Oryzon Genomics SA (ORYZF)
3.645
-0.06
(-1.49%)
USD |
OTCM |
Jun 10, 16:00
Oryzon Genomics Total Liabilities (Quarterly) : 26.97M for March 31, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 26.97M |
| December 31, 2025 | 31.33M |
| September 30, 2025 | 34.09M |
| June 30, 2025 | 28.32M |
| March 31, 2025 | 23.71M |
| December 31, 2024 | 22.44M |
| September 30, 2024 | 25.73M |
| June 30, 2024 | 25.89M |
| March 31, 2024 | 26.87M |
| December 31, 2023 | 27.75M |
| September 30, 2023 | 24.37M |
| June 30, 2023 | 28.48M |
| March 31, 2023 | 29.96M |
| December 31, 2022 | 33.22M |
| September 30, 2022 | 34.08M |
| June 30, 2022 | 27.41M |
| March 31, 2022 | 26.23M |
| December 31, 2021 | |
| September 30, 2021 | 24.29M |
| June 30, 2021 | 24.13M |
| March 31, 2021 | 25.04M |
| Date | Value |
|---|---|
| December 31, 2020 | 22.24M |
| September 30, 2020 | 23.04M |
| June 30, 2020 | 25.20M |
| March 31, 2020 | 18.79M |
| December 31, 2019 | 21.29M |
| September 30, 2019 | 20.02M |
| June 30, 2019 | 22.25M |
| March 31, 2019 | 23.90M |
| December 31, 2018 | 25.52M |
| September 30, 2018 | 25.92M |
| June 30, 2018 | 27.70M |
| March 31, 2018 | 31.65M |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | 24.92M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Pharma Mar SA | 155.18M |
| Grifols SA | 14.09B |
| ACADIA Pharmaceuticals, Inc. | 357.16M |
| Alkermes Plc | 2.507B |
| Alnylam Pharmaceuticals, Inc. | 4.054B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 163.27M |
| Shareholders Equity (Quarterly) | 120.20M |
| Debt to Equity Ratio | 0.0681 |
| Current Ratio | 1.834 |
| Net Debt Paydown Yield | 0.66% |